Aegerion Pharmaceuticals (AEGR) Earns Daily Coverage Optimism Rating of -0.03

News headlines about Aegerion Pharmaceuticals (NASDAQ:AEGR) have been trending somewhat negative on Monday, Accern Sentiment reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aegerion Pharmaceuticals earned a daily sentiment score of -0.03 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 44.5971179056692 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of Aegerion Pharmaceuticals (NASDAQ AEGR) opened at $1.97 on Monday. Aegerion Pharmaceuticals has a 1 year low of $1.23 and a 1 year high of $10.85. The firm has a market capitalization of $56.69, a PE ratio of -0.33 and a beta of 0.50. The company has a debt-to-equity ratio of -19.22, a quick ratio of 0.67 and a current ratio of 1.02.

WARNING: This news story was first posted by Week Herald and is owned by of Week Herald. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.

Insider Buying and Selling by Quarter for Aegerion Pharmaceuticals (NASDAQ:AEGR)

Receive News & Ratings for Aegerion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply